drugset / Trial / NCT00648388

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg

NCT00648388

Phase 1 Completed 44 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's cilostazol 100 mg tablets and Otsuka's Pletal® 100 mg tablets following a single, oral 100 mg(1 x 100 mg) dose administered under fasting conditions.

Timeline

Start
2004-03
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 100 mg Oral

Indications

No indication recorded.